KR102891465B1 - 뇌졸중으로부터의 회복을 위한 방법 및 조성물 - Google Patents

뇌졸중으로부터의 회복을 위한 방법 및 조성물

Info

Publication number
KR102891465B1
KR102891465B1 KR1020187012006A KR20187012006A KR102891465B1 KR 102891465 B1 KR102891465 B1 KR 102891465B1 KR 1020187012006 A KR1020187012006 A KR 1020187012006A KR 20187012006 A KR20187012006 A KR 20187012006A KR 102891465 B1 KR102891465 B1 KR 102891465B1
Authority
KR
South Korea
Prior art keywords
stroke
pharmaceutical composition
composition according
hours
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187012006A
Other languages
English (en)
Korean (ko)
Other versions
KR20180101322A (ko
Inventor
존 자한기르 알람
Original Assignee
이아이피 파마 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이아이피 파마 엘엘씨 filed Critical 이아이피 파마 엘엘씨
Publication of KR20180101322A publication Critical patent/KR20180101322A/ko
Application granted granted Critical
Publication of KR102891465B1 publication Critical patent/KR102891465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187012006A 2015-10-26 2016-10-26 뇌졸중으로부터의 회복을 위한 방법 및 조성물 Active KR102891465B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246574P 2015-10-26 2015-10-26
US62/246,574 2015-10-26
PCT/US2016/058804 WO2017075013A1 (en) 2015-10-26 2016-10-26 Methods and compositions for recovery from stroke

Publications (2)

Publication Number Publication Date
KR20180101322A KR20180101322A (ko) 2018-09-12
KR102891465B1 true KR102891465B1 (ko) 2025-11-25

Family

ID=58631977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012006A Active KR102891465B1 (ko) 2015-10-26 2016-10-26 뇌졸중으로부터의 회복을 위한 방법 및 조성물

Country Status (5)

Country Link
EP (1) EP3368040B1 (https=)
JP (1) JP6889493B2 (https=)
KR (1) KR102891465B1 (https=)
CN (1) CN108348524A (https=)
WO (1) WO2017075013A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
WO2020108659A1 (zh) * 2018-11-30 2020-06-04 上海医药集团股份有限公司 含氮杂环类化合物及其组合物、制备方法和应用
JP7384341B1 (ja) 2023-07-07 2023-11-21 学校法人冬木学園 脳卒中患者の身体の痛みの改善を目的とするリハビリテーションの効果を予測するための方法、及び、システム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007616A1 (en) 2014-07-09 2016-01-14 Eip Pharma, Llc Methods for treating neurologic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE60319073T2 (de) * 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
CA2726588C (en) * 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US9816336B2 (en) 2014-07-08 2017-11-14 Halliburton Energy Services, Inc. Real time conformance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007616A1 (en) 2014-07-09 2016-01-14 Eip Pharma, Llc Methods for treating neurologic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VX-745 Vertex Pharmaceuticals, Current Opinion in Investigational Drugs, 2(8):1070-1076 (2001)*

Also Published As

Publication number Publication date
EP3368040A1 (en) 2018-09-05
KR20180101322A (ko) 2018-09-12
EP3368040A4 (en) 2019-05-29
EP3368040B1 (en) 2022-08-17
JP2018531961A (ja) 2018-11-01
CN108348524A (zh) 2018-07-31
JP6889493B2 (ja) 2021-06-18
WO2017075013A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
JP6660369B2 (ja) 神経障害を治療する方法
AU2018250214B2 (en) Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
JP2010528016A (ja) 細胞を刺激するための方法および組成物
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
KR20170013890A (ko) Nmdar 조절 화합물의 조합물
CA2664099A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
AU2014368961A2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
OA12554A (en) Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders.
EA030333B1 (ru) Способ лечения и/или предотвращения расстройств настроения
US9427439B1 (en) Methods and compositions for recovery from stroke
ES2334241T3 (es) Compuestos para tratar la esquizofrenia y/o anomalias en la regulacion de glucosa.
JP2020203908A (ja) 疼痛の治療のためのｖａｐ−１阻害剤
AU2011323899A1 (en) Methods of treatment and/or prevention of scleroderma, UV injury or sunburn, formation of scars or keloids by using haloaryl substituted Aminopurines
KR20240017910A (ko) 인지 향상제로서 line-1 억제제
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
ES2365905T3 (es) Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
HK1260485A1 (en) Methods and compositions for recovery from stroke
HK1260485B (en) Methods and compositions for recovery from stroke
HK40068517A (en) Methods for treating neurologic disorders
CN121039109A (zh) 3,5-二氨基三唑衍生物及其用于治疗眼部疾病的用途
WO2025188952A1 (en) Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
CA3111433A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)